secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2026-05-12T20:14:35+00:00
Accession:  0001357459-26-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio Q1 2026: Cash $132.6M; R&D spend up 6.4x; PALI-2108 Phase 2 UC starts Q3 2026
--------------------------------------------------------------------------------

- Cash and equivalents of $132.6M at March 31, 2026, sufficient through Phase 2 UC readout (2H 2027) and CD readout (early 2028).
- R&D expense $6.4M in Q1 2026 vs $1.0M in Q1 2025 (+$5.4M) driven by PALI-2108 clinical and CMC costs.
- G&A expense $4.4M in Q1 2026 vs $1.4M in Q1 2025 (+$3.0M) on higher employee costs and professional fees.
- Completed Phase 1a/b for PALI-2108; Phase 1b FSCD cohort showed sustained exposure above IC90 and modulation of inflammatory/fibrotic pathways.
- IND for Phase 2 UC expected 2Q 2026; Phase 2 UC trial start Q3 2026; Phase 2 CD trial start Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000135745926000011/0001357459-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000135745926000011/pali-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001357459-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer